Below are the most recent publications written about "Cross Reactions" by people in Profiles.
-
Ganta KK, McManus M, Blanc R, Wang Q, Jung W, Brody R, Carrington M, Paris R, Chandramouli S, McNamara RP, Luzuriaga K. Acute infectious mononucleosis generates persistent, functional EBNA-1 antibodies with high cross-reactivity to alpha-crystalline beta. Cell Rep. 2025 May 27; 44(5):115709.
-
Katzelnick LC, Zambrana JV, Elizondo D, Collado D, Garcia N, Arguello S, Mercado JC, Miranda T, Ampie O, Mercado BL, Narvaez C, Gresh L, Binder RA, Ojeda S, Sanchez N, Plazaola M, Latta K, Schiller A, Coloma J, Carrillo FB, Narvaez F, Halloran ME, Gordon A, Kuan G, Balmaseda A, Harris E. Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Sci Transl Med. 2021 Oct 06; 13(614):eabg9478.
-
Rouers A, Chng MHY, Lee B, Rajapakse MP, Kaur K, Toh YX, Sathiakumar D, Loy T, Thein TL, Lim VWX, Singhal A, Yeo TW, Leo YS, Vora KA, Casimiro D, Lim B, Tucker-Kellogg L, Rivino L, Newell EW, Fink K. Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection. Cell Rep Med. 2021 05 18; 2(5):100278.
-
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol. 2021; 12:675679.
-
James J, Rhodes S, Ross CS, Skinner P, Smith SP, Shipley R, Warren CJ, Goharriz H, McElhinney LM, Temperton N, Wright E, Fooks AR, Clark TW, Brookes SM, Brown IH, Banyard AC. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses. 2021 04 20; 13(4).
-
Karnaneedi S, Huerlimann R, Johnston EB, Nugraha R, Ruethers T, Taki AC, Kamath SD, Wade NM, Jerry DR, Lopata AL. Novel Allergen Discovery through Comprehensive De Novo Transcriptomic Analyses of Five Shrimp Species. Int J Mol Sci. 2020 Dec 22; 22(1).
-
Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021 01 21; 184(2):476-488.e11.
-
Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, Amcheslavsky A, Kurt Yilmaz N, Buttigieg KR, Elmore MJ, Godwin K, Coombes N, Toomey JR, Schneider R, Ramchetty AS, Close BJ, Chen DY, Conway HL, Saeed M, Ganesa C, Carroll MW, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun. 2020 08 21; 11(1):4198.
-
King LB, Milligan JC, West BR, Schendel SL, Ollmann Saphire E. Achieving cross-reactivity with pan-ebolavirus antibodies. Curr Opin Virol. 2019 02; 34:140-148.
-
Devarajan P, Swain SL. Original Antigenic Sin: Friend or Foe in Developing a Broadly Cross-Reactive Vaccine to Influenza? Cell Host Microbe. 2019 03 13; 25(3):354-355.